USFDA Inspection of Pithampur Facility Results in Three Observations
What happened
The United States Food and Drug Administration conducted a Pre-Approval Inspection at a manufacturing facility in Pithampur, which ran from October 15, 2026, to October 23, 2026. Following the inspection, the company received three observations issued in Form FDA 483. The company confirmed it will work with the United States Food and Drug Administration to address these observations within the required timeframe.
From equitybulls.com
Why it matters
The inspection relates to regulatory oversight of pharmaceutical manufacturing in India. Receiving observations from the United States Food and Drug Administration indicates that the facility must address specific compliance issues to maintain its regulatory standing.
From equitybulls.com
Who's involved
- United States Food and Drug AdministrationConducted the Pre-Approval Inspection at the manufacturing facility.
Keep exploring
The entities involved
-
United States Food and Drug Administration
agency of the US Department of Health and Human Services
-
Pithampur
human settlement in India
Nothing else this week.